Trevi Long Term Debt from 2010 to 2024
| TRVI Stock | USD 2.88 0.04 1.37% |
Long Term Debt | First Reported 2010-12-31 | Previous Quarter 2.5 M | Current Value 2.3 M | Quarterly Volatility 4.1 M |
Check Trevi Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trevi Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 5 M, Discontinued Operations of 0.0 or Interest Expense of 696.1 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0407 or PTB Ratio of 1.69. Trevi financial statements analysis is a perfect complement when working with Trevi Therapeutics Valuation or Volatility modules.
Trevi | Long Term Debt |
Latest Trevi Therapeutics' Long Term Debt Growth Pattern
Below is the plot of the Long Term Debt of Trevi Therapeutics over the last few years. Long-term debt is a debt that Trevi Therapeutics has held for over one year. Long-term debt appears on Trevi Therapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Trevi Therapeutics balance sheet is the sum of the balances of all categories of long-term debt. It is debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years. Trevi Therapeutics' Long Term Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trevi Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Long Term Debt | 10 Years Trend |
|
Long Term Debt |
| Timeline |
Trevi Long Term Debt Regression Statistics
| Arithmetic Mean | 5,363,308 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 76.16 | |
| Mean Deviation | 2,729,344 | |
| Median | 5,117,000 | |
| Standard Deviation | 4,084,504 | |
| Sample Variance | 16.7T | |
| Range | 14M | |
| R-Value | 0.02 | |
| Mean Square Error | 18T | |
| R-Squared | 0.0003 | |
| Significance | 0.95 | |
| Slope | 15,160 | |
| Total Sum of Squares | 233.6T |
Trevi Long Term Debt History
Other Fundumenentals of Trevi Therapeutics
Trevi Therapeutics Long Term Debt component correlations
About Trevi Therapeutics Financial Statements
Investors use fundamental indicators, such as Trevi Therapeutics' Long Term Debt, to determine how well the company is positioned to perform in the future. Although Trevi Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Long Term Debt | 2.5 M | 2.3 M | |
| Long Term Debt Total | 2.5 M | 2.3 M | |
| Short and Long Term Debt | 6.3 M | 4.2 M | |
| Short and Long Term Debt Total | 1.3 M | 1.3 M | |
| Long Term Debt To Capitalization | 0.02 | 0.02 |
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out the analysis of Trevi Therapeutics Correlation against competitors. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.